ÂÜÀòÂÒÂ×

Dr. Jay Short is Co-founder of BioAtla and Co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) platform. He also cofounded Diversa Corporation (now BASF), a pioneering developer of enzymes, antibodies and biologically active compounds, and served in multiple roles including CEO, President and CTO from 1994 to 2005. He led Diversa's public offering, raising over $200 million, which was the largest biotechnology IPO at that time. Prior to Diversa, Jay served as President of Stratacyte, an antibody engineering company and subsidiary of Stratagene (now Agilent), which together with Scripps Clinic was the first to clone and screen human antibody libraries in E. coli. Jay received his B.A in Chemistry with Honors from Taylor University. At Case Western Reserve University he received his Ph.D. in Biochemistry with additional studies in Macromolecular Science. He is the author of more than 100 publications and is the inventor of over 500 issued patents.